It has come to our notice that certain fraudulent individuals or entities are misusing our Company’s name and TCI’s registered trademarks by promoting and offering regulated and hazardous chemical substances through online platforms like YouTube. We hereby categorically clarify that TCI has no association or connection whatsoever with the products being displayed or sold in the videos. These products have been falsely represented as being associated with TCI, and the unauthorized use of our trademark and brand name is both illegal and misleading. TCI Chemicals markets and sells its products exclusively through its official website and authorized distributors. If you become aware of any such fraudulent activity or require clarification, you may reach out to us at: Sales-IN@TCIchemicals.com. Click Here to View the Caution Notice.
Product Document Searching Made Easy by 2D Code! | [Product Highlights] Endogenous Biotin-Blocking Reagent...Maximum quantity allowed is 999
Please select the quantity
Bone Resorption Inhibitor
No.160(January 2014)

Bisphosphonates (BPs), including minodronate, ibandronate, etc., are very effective inhibitors of bone resorption in vivo and in vitro. Minodronate monohydrate (1) is one of BPs.1,2) These compounds are characterized by two C-P bonds which are located on the same carbon atom, i.e. geminal BPs, and have been used for many research studies regarding bone metabolism.1,2)
According to differences in the side chain, BPs can be divided into two groups, non-nitrogen containing BPs (non-N-BPs) and nitrogen-containing BPs (N-BPs). 1 is a N-BP and is classified as a third-generation heterocyclic N-BP.2,3) N-BPs inhibit farnesyl pyrophosphate synthetase, a key enzyme in the mevalonate pathway, which affects cellular activity and survival.1,2) Regarding inhibition of bone resorption, 1, as well as zoledronic acid, is more effective than other BPs.4)
According to differences in the side chain, BPs can be divided into two groups, non-nitrogen containing BPs (non-N-BPs) and nitrogen-containing BPs (N-BPs). 1 is a N-BP and is classified as a third-generation heterocyclic N-BP.2,3) N-BPs inhibit farnesyl pyrophosphate synthetase, a key enzyme in the mevalonate pathway, which affects cellular activity and survival.1,2) Regarding inhibition of bone resorption, 1, as well as zoledronic acid, is more effective than other BPs.4)
References
- 1)Bisphosphonates from bench to bedside
- 2)Computational insights into binding of bisphosphonates to farnesyl pyrophosphate synthase
- 3)A review of minodronic acid hydrate for the treatment of osteoporosis
- 4) Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates
The prices are subject to change without notice. Please confirm the newest price by our online catalog before placing an order.
In addition, sales products changes with areas. Please understand that a product is not available when the product details page is not displayed.
In addition, sales products changes with areas. Please understand that a product is not available when the product details page is not displayed.